Anxiolytics and antidepressants for smoking cessation

Area of Science:

• Pharmacology
• Addiction Medicine
• Psychiatry

Background:

• Anxiety and depression are common symptoms of nicotine withdrawal.
• Smoking cessation can precipitate or worsen depression.
• Smoking may be linked to neurotransmitter deficits (dopamine, serotonin, norepinephrine) targeted by certain medications.

Purpose of the Study:

• To evaluate the efficacy of antidepressants and anxiolytics in achieving long-term smoking cessation.
• To review randomized trials of specific drugs including bupropion, nortriptyline, and various anxiolytics.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) from the Cochrane Tobacco Addiction Group trials register.
• Included trials compared anxiolytic or antidepressant drugs against placebo or alternative therapies.
• Excluded trials with less than six months of follow-up; meta-analysis was performed where appropriate.

Main Results:

• Anxiolytics (e.g., diazepam, buspirone) demonstrated no significant effectiveness in aiding smoking cessation.
• Antidepressants bupropion and nortriptyline were found to increase smoking cessation rates.
• Combination therapy with bupropion and nicotine patch showed higher quit rates than patch alone.

Conclusions:

• Anxiolytics provide minimal support for smoking cessation.
• Specific antidepressants, namely bupropion and nortriptyline, show promise in aiding smokers to quit.
• Further investigation is required to determine if the observed antidepressant effects are drug-specific or a broader class effect.